| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/04/2004 | US6730324 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 05/04/2004 | CA2069600C Fatty acid compositions |
| 04/29/2004 | WO2004035813A2 Screening molecules with anti-prion activity: kits, methods and screened molecules |
| 04/29/2004 | WO2004035779A1 Biomolecule transfer method using virus envelope and composition and system therefor |
| 04/29/2004 | WO2004035586A1 Pyrrolo[1,2-b]pyridazine compounds and their uses |
| 04/29/2004 | WO2004035581A1 Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
| 04/29/2004 | WO2004035561A1 3-(cyclopenten-1-yl)-benzyl- or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia |
| 04/29/2004 | WO2004035556A1 Substituted piperazines, (1,4) diaszepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists |
| 04/29/2004 | WO2004035548A1 Novel compounds |
| 04/29/2004 | WO2004035544A1 Benzo[d]azepine derivatives for the treatment of neurological and psychiatric disorders |
| 04/29/2004 | WO2004035536A2 Azo compounds for type i phototherapy |
| 04/29/2004 | WO2004035534A2 Novel compounds having a dopaminergic and/or serotoninergic activity |
| 04/29/2004 | WO2004035086A2 Method for treatment of demyelinating central nervous system disease using gm-csf |
| 04/29/2004 | WO2004035068A1 Use of enteric glia to promote functional nerve connections |
| 04/29/2004 | WO2004035065A1 Hypoglycemic substances containing zinc |
| 04/29/2004 | WO2004035056A1 Use of skca channel blocking drugs for combating parkinson's disease |
| 04/29/2004 | WO2004035053A1 Neurotrophic factor production promoter |
| 04/29/2004 | WO2004035046A1 Powder inhalant of sumatriptan and the method of preparation thereof |
| 04/29/2004 | WO2004035041A1 Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors |
| 04/29/2004 | WO2004035040A1 Enhancement of alcohol metabolism |
| 04/29/2004 | WO2004035037A2 Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
| 04/29/2004 | WO2004035027A1 Pharmaceutical formulation of olanzapine |
| 04/29/2004 | WO2004019868A3 N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| 04/29/2004 | WO2004011402A3 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 04/29/2004 | WO2003104282A8 Glycoprotein vi - fc fusion protein for treating vascular disorders |
| 04/29/2004 | WO2003104255A3 Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives as ligands for the neuropeptide y5 receptor |
| 04/29/2004 | WO2003087408A3 Schizophrenia associated genes |
| 04/29/2004 | WO2003087368A3 Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| 04/29/2004 | WO2003087367A3 Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
| 04/29/2004 | WO2003086282A3 Nitric oxide donors, compositions and methods of use |
| 04/29/2004 | WO2003015612A9 Materials and methods to promote repair of nerve tissue |
| 04/29/2004 | WO2003013537A9 Irinotecan for treatment of cancer |
| 04/29/2004 | WO2003013536A9 Methods for treatment of cancer using irinotecan based on ugt1a1 |
| 04/29/2004 | WO2003013535A9 Use of irinotecan for improved treatment of cancer based on mdr1 |
| 04/29/2004 | WO2003013534A9 Methods for the treatment of cancer with irinotecan based on cyp3a5 |
| 04/29/2004 | WO2003013533A9 Methods for improved treatment of cancer with irinotecan based on mrp1 |
| 04/29/2004 | WO2003010196A3 Variants and exons of the glyt1 transporter |
| 04/29/2004 | WO2003009807A3 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 04/29/2004 | WO2003007934A8 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 04/29/2004 | WO2003003004A3 Method for identifying compounds the specifically deplete mast cells |
| 04/29/2004 | WO2002079169A8 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 04/29/2004 | WO2002072630A3 Nucleic acid-associated proteins |
| 04/29/2004 | WO2002070669A3 Secreted proteins |
| 04/29/2004 | WO2002064134A8 Use of calcium indomethacin for the treatment of cyclo-oxygenase 2-mediated pathologies |
| 04/29/2004 | WO2002018341A8 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors |
| 04/29/2004 | WO2001095899A8 Pharmaceutical compositions comprising cannabidiol derivatives |
| 04/29/2004 | US20040083447 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands |
| 04/29/2004 | US20040082807 Novel salt forms of poorly soluble probucol esters and ethers |
| 04/29/2004 | US20040082789 Thieno[2,3-c]iosquinolines for use as inhibitors of parp |
| 04/29/2004 | US20040082787 Chemical compounds |
| 04/29/2004 | US20040082784 Anxiolytic agents; antidepressants; Alzheimer, Huntington, Parkinson disease |
| 04/29/2004 | US20040082781 Bicyclic nitrogenous fused-ring compound |
| 04/29/2004 | US20040082763 Diagnosis, therapy of Alzheimer's disease; synthetic antibody |
| 04/29/2004 | US20040082666 Antiserotonine agents |
| 04/29/2004 | US20040082664 Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition |
| 04/29/2004 | US20040082661 Urea derivatives having vanilloid receptor (vr1) antagonist activity |
| 04/29/2004 | US20040082658 Side-chain halogenated amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases |
| 04/29/2004 | US20040082656 Higher unsaturated fatty acid composition |
| 04/29/2004 | US20040082653 Using prostaglandin antagonist |
| 04/29/2004 | US20040082642 Novel estrogen receptor ligands and method III |
| 04/29/2004 | US20040082631 Pyrazole compositions useful as inhibitors of ERK |
| 04/29/2004 | US20040082619 Pyridone derivatives having affinity for cannabinoid 2-type receptor |
| 04/29/2004 | US20040082617 Sulphones which modulate the action of gamma secretase |
| 04/29/2004 | US20040082603 2,3-Dihydro-isoindol-1-one derivatives |
| 04/29/2004 | US20040082602 Kinase inhibitor; analgesics; antiarthritic agents; antihistamines; gastrointestinal disorders |
| 04/29/2004 | US20040082597 Use of CRF antagonists and related compositions |
| 04/29/2004 | US20040082596 Novel carbamate-substituted pyrazolopyridine derivatives |
| 04/29/2004 | US20040082594 Novel uses of combined 5-ht 1a agonists and serotonin reuptake inhibitors |
| 04/29/2004 | US20040082592 Metabotropic glutamate receptor antagonists |
| 04/29/2004 | US20040082589 Quinoline derivatives as nk-3 and nk-2 antagonists |
| 04/29/2004 | US20040082579 Substituted-4-quinolones |
| 04/29/2004 | US20040082575 Compounds and methods for modulation of estrogen receptors |
| 04/29/2004 | US20040082573 Anxiolytic agents with reduced sedative and ataxic effects |
| 04/29/2004 | US20040082572 Benzodiazepine derivatives as app modulators |
| 04/29/2004 | US20040082569 Novel substituted amides, their preparation and use |
| 04/29/2004 | US20040082566 Pyrrolidine sulfonamides |
| 04/29/2004 | US20040082563 Thrombosis therapy; antitumor agents; anticoagulants; Factor x inhibitors; anticholesterol agents; cardiovascular disorders; antiinflammatory agents |
| 04/29/2004 | US20040082555 Use of gaba, inverse agonists in combination with nicotine receptor partial agonist, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders |
| 04/29/2004 | US20040082551 Novel pyrazoles and their use as p38 kinase inhibitors |
| 04/29/2004 | US20040082548 Cardiovascular disorders; Alzheimer's disease; anticholesterol agents |
| 04/29/2004 | US20040082543 Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
| 04/29/2004 | US20040082542 Useful as modulators of interaction between receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, beta-amyloid and amphoterin |
| 04/29/2004 | US20040082531 Containing a transcription regulatory sequence derived from Human Cytomegalovirus major immediate early gene that includes exon 1, but not intron A; use of such vectors in vaccine and pharmaceutical compositions and gene therapy |
| 04/29/2004 | US20040082516 For in vitro/vivo drugs; neuropathy |
| 04/29/2004 | US20040082499 Perturbed membrane-binding compounds |
| 04/29/2004 | US20040082014 Method and test system for identifying substances which protect nerve cells |
| 04/29/2004 | US20040081972 Detecting antibodies; screening, development therapies for infections, inflammation; polypeptides; monoclonal antibodies |
| 04/29/2004 | US20040081971 Gastrointestinal disorders; cardiovascular disorders; autoimmune diseases; cell proliferation; antiinflammatory agents |
| 04/29/2004 | US20040081693 Capable of releasing the drug at a constant rate following zero order kinetics for 24 hours or more |
| 04/29/2004 | US20040081685 Plurality of patch units connected along one or more borders divisible into respective units allowing dosage to be adjusted |
| 04/29/2004 | US20040081624 Mixture containing high volatility carrier; vaporization; mixing with air |
| 04/29/2004 | DE10294485T5 Mit Mnk-Kinase homologe Proteine, die in die Regulation der Energiehomöostase und den Organellenmetabolismus involviert sind Mnk homologous proteins with kinase, that are involved in the regulation of energy homeostasis and the metabolism organelle |
| 04/29/2004 | DE10248925A1 Neue Verbindungen mit dopaminerger und/oder serotoninerger Aktivität New connections with dopaminergic and / or serotonergic activity |
| 04/29/2004 | CA2510355A1 Use of enteric glia to promote functional nerve connections |
| 04/29/2004 | CA2503075A1 Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
| 04/29/2004 | CA2502249A1 Substituted piperazines, (1,4) diaszepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists |
| 04/29/2004 | CA2502211A1 Azo compounds for type i phototherapy |
| 04/29/2004 | CA2501418A1 Novel compounds |
| 04/29/2004 | CA2500417A1 Neurotrophic factor production promoter |
| 04/29/2004 | CA2497780A1 Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors |